Enhanced Trial Shifts to Five-Year Monitoring After 91% Athlete Testosterone Use
Enhanced's IRB-approved ASCEND001 clinical trial has concluded its 12-week interventional phase and begun a five-year observational period, covering 36 of 42 athletes. Aggregate data shows 91% used testosterone esters, 79% hGH, 62% stimulants, 50% metabolic modulators and 41% EPO ahead of the May 24 Enhanced Games.
1. IRB-Approved ASCEND001 Trial Update
Enhanced has posted its IRB-approved ASCEND001 study on ClinicalTrials.gov, marking the end of its 12-week interventional phase and the start of a five-year observational monitoring period. The trial enrolled 36 of 42 competing athletes under individualized, doctor-prescribed FDA-approved protocols to assess safety and tolerability.
2. Aggregate Substance Usage Data
Preliminary aggregate results reveal 91% of participating athletes used testosterone esters, 79% used human growth hormone, 62% used stimulants such as Adderall, 50% used metabolic modulators like anastrozole alongside anabolic agents, and 41% used erythropoietin (EPO). All substances were legally approved and no banned peptides were included.
3. Strategic Implications for Enhanced
These proprietary clinical results underpin Enhanced’s competitive moat and inform its Live Enhanced consumer platform, translating elite athlete protocols into personalized health and performance products. The timing ahead of the May 24 Enhanced Games spotlights the company’s research-driven positioning in performance medicine.